undamentalytics Newsletter
Sign in

Maxcyte, Inc. balance sheet

At the end of fiscal 2025, Maxcyte, Inc. had total assets of $203m, total liabilities of $31.0m and shareholders' equity of $171m. It held $20.1m in cash against $0 of debt: net cash of $20.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents1519481147282015
Receivables—57116544
Inventory—45912988
Total current assets—45270252190172118121
Total assets—52284287268239203185
Accounts payable—1201112
Deferred revenue (current)—5775542
Total current liabilities—12161518161410
Long-term debt—5——————
Total debt05—00000
Total liabilities—19213336333126
Shareholders' equity1433263254232206171159
Net debt (negative = net cash)−15−14−48−11−47−28−20−15
Shares outstanding—77m101m102m104m106m107m106m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BNGO vs MXCTMXCT vs RPIDMXCT vs OABI

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Maxcyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Maxcyte, Inc.